Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Arbyn M, Castellsague X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011;22:2675-86
   PubMed Web of Science ®Google Scholar
• zur Hausen H. The search for infectious causes of human cancers: where and why (Nobel lecture). Angew Chem Int Ed Engl 2009;48:5798-808
   PubMed Web of Science ®Google Scholar
• Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl cancer Inst 2010;102:1478-88
   PubMedGoogle Scholar
• zur Hausen H. Human papillomavirus & cervical cancer. Indian J Med Res 2009;130:209-15
   PubMedGoogle Scholar
• American Congress of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 131: screening for cervical cancer. Obstet Gynecol 2012;120:1222-38
   PubMedGoogle Scholar
• NHSCSP audit of invasive cervical cancer. National report 2007–2010. Available from: www.cancerscreening.nhs.uk/cervical/publications/nhscsp-audit-invasive-cervical-cancer-201107.pdf [Last accessed 9 June 2014]
   Google Scholar
• Gage JC, Schiffman M, Solomon D, et al. Risk of precancer determined by HPV genotype combinations in women with minor cytologic abnormalities. Cancer Epidemiol Biomarkers Prev 2013;22:1095-101
   PubMedGoogle Scholar
• Kinney WK, Manos MM, Hurley LB, Ransley JE. Where’s the high-grade cervical neoplasia? The importance of minimally abnormal Papanicolaou diagnoses. Obstet Gynecol 1998;91:73-6
   Google Scholar
• Centers for Disease Control and prevention. Available from: www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf [Last accessed 26 May 2014]
   Google Scholar
• Killeen JL, Dye T, Grace C, Hiraoka M. Improved abnormal pap smear triage using cervical cancer biomarkers. J Low Genit Tract Dis 2014;18:1-7
   PubMedGoogle Scholar
• Monsonego J, Bosch FX, Coursaget P. Cervical cancer control, priorities and new directions. Int J Cancer 2004;108:329-33
   PubMed Web of Science ®Google Scholar
• ASCUS-LSIL Triage Study (ALTS) group. A randomized trial on the management of cytology interpretation of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92
   PubMed Web of Science ®Google Scholar
• ASCUS-LSIL Triage Study (ALTS) group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretation. Am J Obstet Gynecol 2003;188:1393-400
   PubMed Web of Science ®Google Scholar
• Basu P, Samaddar A, Mittal S, et al. Concordance between hybrid capture 2 results performed on cervical samples obtained before and immediately after visual inspection with acetic acid test. Int J Prev Med 2014;5:191-5
   PubMedGoogle Scholar
• Solomon D. Role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr 2003;1:97-101
   Google Scholar
• Verdoodt F, Szarewski A, Halfon P, et al. Triage of women with minor abnormal cervical cytology. Cancer Cytopathol 2013;121:675-87
   PubMed Web of Science ®Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008;26:29-41
   PubMed Web of Science ®Google Scholar
• Jakobsson M, Tarkkanen J, Auvinen E, et al. Colposcopy referral rate can be reduced by high-risk human Papillomavirus triage in the management of recurrent atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion cytology in Finland. Int J STD AIDS 2012;23:485-9
   PubMedGoogle Scholar
• ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Cervical cytology screening. Number 45, August 2003. Obstet Gynecol 2003;102:417-27
   PubMedGoogle Scholar
• Ronco G, Biggeri A. Confortini M, et al. health technology assessment report: HPV-DNA based primary screening for cervical cancer precursor. Epidemiol Prev 2012;36:1-72
   Google Scholar
• Knoff J, Yang B, Hung CF, Wu TC. Cervical cancer: development of targeted therapies beyond molecular pathogenesis. Curr Obstet Gynecol Rep 2014;3:18-32
   PubMedGoogle Scholar
• Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int 2013;2013:519-619
   Google Scholar
• Cherry JJ, Rietz A, Malinkevich A, et al. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PLoS One 2013;8:3-17
   Google Scholar
• Nor Rashid N, Yusof R, Watson RJ. Disruption of pocket protein dream complexes by E7 proteins of different types of human papillomaviruses. Acta Virol 2013;57:447-51
   PubMedGoogle Scholar
• Park JW, Shin MK, Pitot HC, Lambert PF. High incidence of HPV-associated head and neck cancers in FA deficient mice is associated with E7’s induction of DNA damage through its inactivation of pocket proteins. PLoS One 2013;8(9):11-18
   Google Scholar
• Park JW, Shin MK, Lambert PF. High incidence of female reproductive tract cancers in FA-deficient HPV16-transgenic mice correlates with E7’s induction of DNA damage response, an activity mediated by E7’s inactivation of pocket proteins. Oncogene 2013;9:54-67
   Google Scholar
• Kraus I, Molden T, Holm R, et al. Presence of E6 and E7 mRNA from human Papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol 2006;44:1310-17
   PubMed Web of Science ®Google Scholar
• Guess JC, McCance DJ. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3 production. Virol 2005;79:14852-7
   Google Scholar
• Biswas SK, Sodhi A. Effect of monocyte chemoattractant protein-1 on murine bone marrow cells: proliferation, colony-forming ability and signal transduction pathway involved. Int J Immunopathol Pharmacol 2002;15:183-7
   PubMedGoogle Scholar
• Scott M, Nakagawa M, Moscicki A. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol 2001;8:209-13
   PubMedGoogle Scholar
• Doorbar J. The Papillomavirus life cycle. J Clin Virol 2005;32S:S7-S15
   Google Scholar
• Denton KJ, Bergeron C, Klement P, et al. European CINtec Cytology Study Group. The sensitivity and specificity of p16 (INK4a) cytology vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. Am J Clin Pathol 2010;134:12-21
   PubMed Web of Science ®Google Scholar
• Dockter J, Schroder A, Earon B, et al. Analytical characterization of the APTIMA HPV assay. J Clin Virol 2009;45:39-47
   PubMed Web of Science ®Google Scholar
• Narimatsu R, Patterson BK. High-throughput cervical cancer screening with using intracellular human Papillomavirus E6 and E7 mRNA quantification by flow cytometry. Am J Clin Pathol 2005;123:716-23
   PubMed Web of Science ®Google Scholar
• Shen Y, Gong J, He Y, et al. Quantivirus HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test. J Virol Methods 2012;187:288-93
   PubMedGoogle Scholar
• Burger EA, Kornør H, Klemp M, et al. HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review. Gynecol Oncol 2011;120:430-8
   PubMed Web of Science ®Google Scholar
• Cuschieri KS, Whitley MJ, Cubie HA. Human Papillomavirus type specific DNA and RNA persistence-implications for cervical disease progression and monitoring. J Med Virol 2004;73:65-70
   PubMed Web of Science ®Google Scholar
• Molden T, Nygård JF, Kraus I, et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int J Cancer 2005;10:973-7
   Google Scholar
• Benevolo M, Vocaturo A, Caraceni D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test. J Clin Microbiol 2011;49:2643-50
   PubMedGoogle Scholar
• Coleman D, Day N, Douglas G, et al. European guidelines for quality assurance in cervical cancer screening. Eur J Cancer 1993;29(4):1-38
   Google Scholar
• Osservatorio Nazionale Screening. Available from: www.osservatorionazionalescreening.it [Last accessed 7 March 2014]
   Google Scholar
• Mennini FS, Costa S, Favato G, Picardo M. Anti-HPV vaccination: a review of recent economic data for Italy. Vaccine 2009;27:54-61
   PubMed Web of Science ®Google Scholar
• Baio G, Capone A, Marcellini A, et al. Economic burden of human papilloma virus related disease. PLoS One 2012;7:1-9
   Google Scholar
• Arbyn M, Ronco G, Cuzich J, et al. How to evaluate emerging technologies in cervical cancer screening? Int J Cancer 2009;125:2489-96
   PubMed Web of Science ®Google Scholar
• WHO. Immunization financing, supply and procurement. Posted by WHO, Geneva, Switzerland, 3 February 2006. Available from: www.who.int/immunization.supply/en/ [Last accessed 7 March 2014]
   Google Scholar
• Jordan J, Arbyn M, Hirsch PM, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology. Cytopathol 2008;19:342-54
   PubMed Web of Science ®Google Scholar
• Guidelines of the Italian Society of Cervical Pathology and Colposcopy (SICPVCP). Available from: www.colposcopiaitaliana.it/pdf07/Linee-Guida-2006.pdf [Last accessed 7 March 2014]
   Google Scholar
• Guidelines of the Italian Society for Gynaecology and Obstetrics (SIGO). Available from: www.sigo.it/linee-guida-sigo/linee-guida-internazionali.php [Last accessed 7 March 2014]
   Google Scholar
• Ostensson E, Froberg M, Hjerpe A, et al. Economic analysis of human papillomavirus triage, repeat cytology, and immediate colposcopy in management of women with minor cytological abnormalities in Sweden. Acta Obstetricia et Gynecologica 2010;89:1316-25
   PubMed Web of Science ®Google Scholar
• Volante R, Ronco G. National survey on the quality of the second level screening for cervical cancer. Epidemiol Prev 2006;30:49-55
   Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;1:159-74
   Web of Science ®Google Scholar
• Drumond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. Oxford University Press; New York, NY, USA: 2005
   Google Scholar
• Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in health and medicine. Oxford University Press; New York, NY, USA: 1996
   Google Scholar
• Official 2013 National Italian Tariff Formularies. Available from: www.salute.gov.it [Last accessed 7 March 2014]
   Google Scholar
• Giorgi-Rossi P, Ricciardi A, Cohet C, et al. Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. BMC Public Health 2009;9:1-9
   PubMedGoogle Scholar
• Armarnik S, Sheiner E, Piura B, et al. Obstetric outcome following cervical conisation. Arch Gynecol Obstet 2011;283:765-9
   PubMed Web of Science ®Google Scholar
• Zappacosta R, Rosini S. Cervical cancer screening: from molecular basis to diagnostic practice, going through new technologies. Tech Cancer Res Treat 2008;7:1-14
   PubMedGoogle Scholar
• Ferris DG, Litaker MS; ASCUS/LSIL Triage Study (ALTS) Group. Colposcopy quality control by remote review of digitized colposcopic images. Am J Obstet Gynecol 2004;191:1934-41
   PubMedGoogle Scholar
• Szarewski A, Mesher D, Cadman L, et al. A comparison of 7 tests for high grade cervical intraepithelial neoplasia in women with abnormal smears: the Predictors 2 study. J Clin Microbiol 2012;50:1867-73
   PubMed Web of Science ®Google Scholar
• Ratnan S, Coutlee F, Fontaine D, et al. Clinical performances of the PreTect HPV Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at high risk of cervical cancer. J Clin Microbiol 2010;48:2779-85
   PubMedGoogle Scholar
• Monsonego J. Emerging issues on HPV infections from science to practice. Karger; Paris, UK: 2006 pp 82-102.
   Google Scholar
• Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of alternative triage strategies for atypical squamous cell of undetermined significance. JAMA 2002;287:2382-90
   PubMed Web of Science ®Google Scholar
• Škamperle M, Kocjan BJ, Maver PJ, et al. Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe. Acta Dermatovenerol Alp pannonica Adriat 2013;22(1):1-5
   PubMedGoogle Scholar
• Pinkerton SD, Johnson-Masotti AP, Derse A, Layde PM. Ethical issues in cost-effectiveness analysis. Eval Program Plann 2002;25:71-83
   Google Scholar
• Psyrri A, Di Maio D. Human papillomavirus in cervical and head and neck cancer. Nat Clin Prac Oncol 2008;5:24-31
   PubMedGoogle Scholar
• Welters MJ, Kenter G, Piersma SJ, et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin Cancer Res 2008;14:178-87
   PubMed Web of Science ®Google Scholar
• Wentzensen N, Sherman ME, Schiffman M, et al. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009;112:293-9
   PubMed Web of Science ®Google Scholar
• Benevolo M, Terrenato I, Mottolese M, et al. Diagnostic and prognostic validity of the human papillomavirus E6/E7 mRNA test in cervical cytological samples of HC2-positive patients. Cancer Causes Control 2011;22:869-75
   PubMedGoogle Scholar